Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.35 | — | — | — | — | — | — | — | — | — | — | — | 450.00 | 62.41 | 29.99 | 15.40 | 43.03 | 60.15 | — | 32.69 | 30.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | +945.7% | +3.7% | — | -52.9% | +40.6% | +90.2% | — | +39.3% | +39.4% | |
| P/S Ratio | 1.40 | 1.82 | 1.99 | 2.28 | 1.31 | 1.32 | 1.34 | 1.31 | 1.43 | 1.63 | 1.25 | 1.34 | 1.60 | 2.06 | 1.56 | 1.64 | 2.15 | 2.40 | 2.64 | 3.30 | 3.49 |
| — | +37.8% | +48.0% | +73.5% | -8.9% | -18.8% | +7.3% | -2.1% | -10.5% | -20.8% | -19.8% | -18.2% | -25.6% | -14.4% | -40.8% | -50.4% | -38.2% | -46.6% | -22.2% | +20.3% | +57.7% | |
| P/B Ratio | 0.91 | 1.67 | 1.46 | 1.59 | 0.63 | 0.57 | 0.53 | 0.52 | 0.50 | 0.61 | 0.44 | 0.45 | 0.46 | 0.70 | 0.73 | 0.80 | 1.09 | 1.22 | 1.26 | 1.78 | 1.98 |
| — | +192.4% | +178.6% | +207.2% | +24.9% | -5.6% | +20.4% | +16.4% | +10.2% | -13.7% | -40.0% | -44.4% | -58.0% | -42.3% | -42.4% | -54.9% | -44.9% | -52.1% | -30.4% | +8.6% | +63.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 7.85 | — | — | — | 3.07 | 11.54 | 11.09 | 28.19 | 39.95 | 8.48 | 25.98 |
| — | — | — | — | — | — | — | — | — | — | +155.8% | — | — | — | -92.3% | +36.1% | -57.3% | +72.5% | +70.6% | -16.2% | +77.9% | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.33 | 10.24 | 28.60 | 34.49 | — | 22.97 | 20.38 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -55.4% | +40.3% | +53.0% | — | +47.6% | +40.8% | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.09 | 11.27 | 33.56 | 37.77 | — | 24.84 | 21.72 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -54.7% | +54.5% | +58.4% | — | +56.2% | +37.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.0% | 93.0% | 90.0% | 93.3% | 94.7% | 91.5% | 93.0% | 95.1% | 94.6% | 91.1% | 88.5% | 92.4% | 92.1% | 92.4% | 92.4% | 90.3% | 90.3% | 90.6% | 90.6% | 90.8% | 90.3% |
| — | +1.6% | -3.1% | -1.9% | +0.1% | +0.4% | +5.0% | +3.0% | +2.8% | -1.4% | -4.2% | +2.2% | +2.0% | +2.0% | +2.0% | -0.6% | +0.0% | +0.3% | +0.2% | +0.3% | +0.1% | |
| Operating Margin | -70.0% | -126.3% | -97.1% | -70.5% | -55.6% | -73.2% | -89.0% | -19.3% | -23.1% | -20.1% | -19.5% | -15.7% | -15.4% | -6.2% | 3.2% | 10.3% | 6.0% | 5.4% | -12.7% | 12.7% | 15.4% |
| — | -72.5% | -9.1% | -264.9% | -140.9% | -264.2% | -357.5% | -23.3% | -49.5% | -222.9% | -706.8% | -252.4% | -358.1% | -215.8% | +125.2% | -19.0% | -61.2% | -70.5% | -177.2% | -17.8% | +20.2% | |
| Net Margin | -102.0% | -123.7% | -93.9% | -246.8% | -40.1% | -51.7% | -58.9% | -9.2% | -11.2% | -9.0% | -8.7% | -5.3% | 0.4% | 3.3% | 5.2% | 10.6% | 5.0% | 4.0% | -10.7% | 10.4% | 11.1% |
| — | -139.1% | -59.3% | -2571.8% | -259.3% | -478.0% | -574.7% | -74.2% | -3265.1% | -371.2% | -267.9% | -149.8% | -92.9% | -17.4% | +148.7% | +2.3% | -54.8% | -71.9% | -177.4% | -14.0% | +12.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.9% | -25.0% | -16.0% | -35.6% | -4.7% | -5.5% | -5.6% | -0.9% | -1.0% | -0.8% | -0.8% | -0.4% | 0.0% | 0.3% | 0.6% | 1.3% | 0.6% | 0.5% | -1.3% | 1.4% | 1.6% |
| — | -357.6% | -184.4% | -3812.9% | -382.8% | -555.7% | -637.8% | -106.2% | -3983.4% | -394.3% | -224.4% | -133.5% | -96.0% | -44.5% | +147.9% | -7.2% | -60.0% | -75.0% | -168.0% | -22.6% | +16.9% | |
| ROA | -38.5% | -14.8% | -10.5% | -25.9% | -3.7% | -4.3% | -4.6% | -0.8% | -0.8% | -0.7% | -0.6% | -0.4% | 0.0% | 0.2% | 0.5% | 1.1% | 0.5% | 0.4% | -1.1% | 1.2% | 1.4% |
| — | -241.3% | -129.9% | -3331.4% | -348.7% | -524.9% | -618.5% | -102.9% | -3937.9% | -393.1% | -225.3% | -134.1% | -96.0% | -44.3% | +147.4% | -9.4% | -60.8% | -75.6% | -166.8% | -22.7% | +16.4% | |
| ROIC | -32.2% | -23.7% | -15.2% | -9.1% | -5.7% | -7.0% | -7.8% | -1.7% | -1.8% | -1.7% | -1.6% | -1.3% | -1.2% | -0.7% | 0.5% | 1.1% | 0.6% | 0.6% | -1.3% | 1.4% | 1.8% |
| — | -239.7% | -96.0% | -432.2% | -209.5% | -301.2% | -374.7% | -27.3% | -57.6% | -139.4% | -424.3% | -219.6% | -287.1% | -227.1% | +140.0% | -19.7% | -65.7% | -74.0% | -166.2% | -27.9% | +17.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | — | 0.05 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 |
| — | — | +102.7% | +68.1% | +59.7% | +54.0% | +40.0% | +33.0% | -19.1% | -18.6% | -18.1% | -18.3% | -15.8% | -15.8% | -15.9% | -13.7% | -16.7% | -15.3% | -16.0% | -18.5% | -15.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.01 | 1.53 | 2.42 | 2.78 | — | 1.32 | 1.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +15.4% | +118.8% | +182.1% | — | +8.5% | -30.9% | |
| Current Ratio | 2.39 | 1.61 | 2.16 | 2.39 | 3.12 | 3.25 | 3.93 | 4.39 | 4.85 | 4.68 | 4.71 | 4.94 | 6.32 | 6.10 | 5.69 | 5.68 | 5.47 | 5.62 | 5.42 | 6.43 | 6.41 |
| — | -50.4% | -44.9% | -45.5% | -35.8% | -30.6% | -16.6% | -11.1% | -23.3% | -23.3% | -17.3% | -13.1% | +15.5% | +8.6% | +4.9% | -11.6% | -14.6% | -9.4% | -20.4% | +3.6% | +1.0% | |
| Quick Ratio | 2.38 | 1.60 | 2.15 | 2.38 | 3.10 | 3.23 | 3.91 | 4.37 | 4.84 | 4.67 | 4.69 | 4.92 | 6.31 | 6.09 | 5.68 | 5.67 | 5.46 | 5.60 | 5.41 | 6.41 | 6.40 |
| — | -50.4% | -45.0% | -45.6% | -35.9% | -30.7% | -16.7% | -11.2% | -23.4% | -23.4% | -17.4% | -13.1% | +15.7% | +8.7% | +4.9% | -11.6% | -14.7% | -9.5% | -20.4% | +3.7% | +1.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VNDA stock.
Vanda Pharmaceuticals Inc.'s current P/E is -1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vanda Pharmaceuticals Inc.'s current operating margin is -70.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vanda Pharmaceuticals Inc.'s business trajectory between earnings reports.